In the twenty years since the creation of the first effective CAR-T cells, lentiviral vectors have become valuable tools for the development of ex vivo gene and cell therapies. Two ex vivo lentiviral gene therapy products have recently reached the market, one approved for the treatment of acute lymphoblastic leukaemia and the other for beta-thalassemia. The successful development of these treatments has demonstrated the potential for lentiviral therapies to treat cancer and other diseases. Dr . Katie Roberts at OXGENE, explains how scalable manufacture will enable progress for lentiviral therapies.